Clinical Trials

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

17 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Uterine Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT00731952 2017-05-04

Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer

21 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01633645 2015-09-28

Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

53 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00118144 2014-08-21

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

42 enrolled 7 charts

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00118183 2013-06-04

Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

62 enrolled

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

NCT00075751 2013-02-28

Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer

99 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00052338 2013-01-23

Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

34 enrolled

Carcinoma, Non-Small-Cell Lung, Pleural Effusion, Malignant

NCT00040768 2013-01-16

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00411593 2012-02-08

Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00667641 2011-05-10

Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

16 enrolled

Carcinoma, Ovarian Epithelial, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT00117351 2011-02-17

VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

Phase 2 Terminated

Adenocarcinoma, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung

NCT00516100 2010-01-15

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Phase 1/2 Unknown

62 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00343720 2008-03-13

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00051974 2008-02-11

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

155 enrolled